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1. Introduction 
Cervical carcinoma remains a leading cause of death among women in developing 
countries. Because recent advances in the immune pathways of gynaecologic cancers have 
been achieved, this field has become important in the current practice of modern 
oncologists.  
Contemporary investigations have focused on tumor infiltrating lymphocytes, reflecting the 
status of the cellular immune system in different types of cervical carcinoma.  
Despite complex management of cervical cancer according to the risk stratification for 
recurrence and local guidelines (radical hysterectomy, meaning the removal of the uterus 
and cervix, one third of the vagina, the parametrial tissue at the pelvic sidewall and ligature 
of utero-sacrals with or without lymphadenectomy, followed by adjuvant radio and 
chemotherapy), up to 40% of patients still develop relapse of their cancer. 
Since the immune response towards cervical cancer is thought to be important in either 
clearing or controlling the viral infection, the evaluation of local cellular immune response 
seems to be critical for the classification of patients according to their risk for the therapeutic 
decision and also may potentially indicate new adjuvant treatment strategies including 
immunotherapy. Moreover, new predictive biomarkers (including tumor proliferation and 
tumor invasion markers) are essential to identify patients with high risk of relapse and to 
optimize disease management. 
Research on both intra- and peritumoral infiltration of immune cells has lead to a better 
understanding and management of cervical cancer, especially in recognition of new 
predictive biomarkers. Also, the evaluation of local cellular immune response in cervical 
cancer with or without relapse may indicate new strategies in order to improve survival.  
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Nowadays, promising vaccines to prevent the development of Human Papillomavirus (HPV)-
induced cervical carcinoma are already distributed all over the world.  
In addition to the scientific world interest in understanding the mechanisms of mucosal 
HPV carcinogenesis in the less susceptible organs, the findings indicate that HPV type 16 
and 18 vaccines could also potentially protect HPV-vaccinated persons against cancers, 
including the following: anus, vagina, vulva, penis, oral cavity and oropharynx.  
There has been recently a great interest in understanding the role of host’s immune response in 
the natural history of HPV and in particular anti-viral cell mediated immunity. Several studies 
have shown that altered cell mediated immunity is strongly associated with increased HPV 
infection and cervical cancer. Persistent infection with HPV oncogenic types is the most 
important event in the progression to cervical precancerous lesions and cervical cancer. 
Several immune cells subtypes are strongly involved in the cellular immune response after 
exposure to a non-self antigen including mononuclear phagocytes, natural killer (NK) cells, 
polymorph nuclear leukocytes and biochemical factors such as complement system. 
Immune effector system involves essential processes as innate or adaptive that occurs in 
sequences after the exposure to a non-self antigen. After antigen ingestion, activation of NK 
cells allows the recognition of the processed by specific T-cells which play a central role in 
cellular immune response. On the other hand, B-cells control and regulate the humoral 
immune response.  
It is now widely accepted that disease is caused by infection with high risk HPV types 
which may or may not be associated with clinically apparent lesion. Woman who cannot 
clear the viral infection became persistent HPV carriers and constitute the high risk group 
for progression to cervical cancer.  
Current studies have suggested that immunological defects are associated with higher 
prevalence and persistence of HPV infection, especially in individuals with Human 
Immunodeficience Virus (HIV) infection. In addition, some evidences have found that other 
mechanisms than immunosuppression such as interactions between HIV and HPV viral genes 
may influence the increased risk of neoplasia and invasive cancer (Moscicki, 2000; Scott, 2000).  
The anti-viral effects of cellular immunity have been hampered by several factors including 
(i) gene transcription patterns of HPV, (ii) inadequate interpretation, (iii) assessment of HPV 
type specificity.  
Conversely, the lesions caused by HPV infection are generally localized to squamous 
epithelial sites. HPV has learned to evade the host’s immunity through years of co-
evolution, with the consequence that the immune response induced by HPV after natural 
infection, aiming to clear or control an incident infection with oncogenic HPV types, is, 
therefore, attenuated (Goncalves & Donadi, 2004; Hatch, 1999; Piersma, 2007; Scott, 2001; 
Stoler, 2010).  
2. Epidemiology  
The leading cause for human cervical cancer is still represented by HPV infection, a 
common sexually transmitted disease. While the risk for acquiring HPV infection is directly 
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linked to the number and behavior of sexual partners, most infections have a benign clinical 
course and resolve spontaneously. However, up to 10% of women became persistent HPV 
carriers and constitute the high risk group for progression to cervical carcinoma (Goncalves 
& Donadi, 2004; Scott, 2001).  
It is widely recognized that HPV types with specific oncogenic risk include HPV type 16, 
HPV type 18, HPV type 31, HPV type 33, HPV type 35, HPV type 45, HPV type 51, HPV 
type 52, HPV type 58, HPV type 59, 66 and 68. 
Based on its rarity, recurrent respiratory papillomatosis (RRP) recognized as one potential 
manifestation of HPV infection in the airways, gives only unsatisfactory reports.  
Of notice is that for some locations the cases are in men (penile cancer) or both in men or 
women (anal cancer and cancers of the oropharynx and oral cavity) needs to be further 
examined. 
3. Screening and diagnosis 
The most common screening method used to detect high grade squamous intraepithelial 
lesions (HSIL) is conventional cervical cytology, followed by colposcopy and directed 
biopsy. Furthermore, the PAP-test continues to have an unclear meaning.  
Thus, approximately 1/1000 of women will develop cervical carcinoma. 
The findings gained during the last years on persistent high risk HPV types in women 
developing cervical carcinoma have provided the basis for evaluation of the clinical utility of 
testing for cancer-associated HPV types (Ancuta, 2009; Goncalves & Donadi, 2004; Scott, 2001). 
International guidelines recommend screening in women aged 25-50 years every three years 
and in women aged 51-60 years every five years. Women older than 60 years of age are not 
the subject for screening. 
Women who are both vaccinated and test negative for HPV are typically characterized by a 
low risk for emergent cervical disease. In addition, they can be safely reassured for a long time 
prior to their next screening assessment. In contrast, women who are HPV positive could 
undergo cytological testing and follow well-established protocols for clinical assessment. 
It is widely accepted that the evaluation of cervical cancer should include a clinical staging 
system, as well as an imaging and biological assessment. Chest X-ray, intravenous 
urography, cystoscopy and proctoscopy, lymphangiography, CT scan, CT directed lymph 
node aspiration, magnetic resonance imaging (MRI), positive emission tomography (PET) 
scan, blood count, serum chemistry profile and urine analysis are allowable techniques for 
documenting the extent of tumor spread (Goncalves & Donadi, 2004; Scott, 2001). 
4. Management 
The case for beginning to introduce HPV testing as the primary screening test for women 
aged over 30 years is now overwhelming. Different cross-sectional studies have already 
demonstrated a far higher sensitivity for detecting cervical intraepithelial neoplasia grade 2 
(CIN2) or grade 3 (CIN3) than cytology (HPV sensitivity over 95%, cytology sensitivity 
between 55% and 75%), even if a lower specificity was proposed. 
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The variables that can potentially interfere with HPV infection comprise the following 
(Stoler, 2010): 
 Cervical anatomy and the location of the squamo-columnar junction; 
 The nature and size of the biopsy specimen; 
 The location of the biopsy; 
 The number of biopsies; 
 The colposcopic appearance; 
 The orientation on embedding; 
 The depth and the quality of the histologic sections; 
 The criteria used for interpretation; 
 The inter-observer variation amongs pathologists. 
Colposcopy has the sensitivity for the detection of neoplastic disease in the range of 60 to 
70% in the management of women presenting with abnormal cervical cytology and those 
with lesions of intraepithelial disease. However, its sensitivity may be increased into range 
of more than 90% when employed together with exfoliative cytology or HPV-DNA testing 
or both. Therefore, all HPV positive women should be referred for colposcopic evaluation. 
HPV-testing strategy is the preferred management option for women with an equivocal 
cytology derived from a liquid-based PAP sample.  
Women who are ASC-US HPV positive are best managed by colposcopic technique.  
Treatment options classically include surgery, radiotherapy and chemotherapy, while 
modern approach is also based on immunotherapy.  
Immunotherapy represents the manipulation of immunologic processes, namely biologic 
therapy, or the application of biologic response modifiers (BRMs). It is nowadays widely 
recognized that the biologic therapy may have immunologic effects and can act through 
multiple mechanisms such as:  
 to increase the number of effector cells; 
 to decrease host’s suppressor immunologic mechanisms; 
 to make the tumor cells more susceptible to damage by immunologic activity; 
 to improve the host’s tolerance to radiotherapy or chemotherapy (Goncalves & Donadi, 
2004; Nedergaard, 2007; Nedergaard, 2008; Scott, 2001).   
4.1 Passive immunotherapy 
Passive immunotherapy techniques have been used in some melanoma and renal carcinoma 
patients resulting in objective responses. Because the lymphokine-activated killer cells 
(LAK) plus interleukin-2 (IL-2) technique is associated with significant toxicity, variations of 
these methods need further studied (Monie, 2007; Scott,, 1997; Scott, 2001; Wang, 1999). 
4.2 Passive humoral immunotherapy 
The passive humoral immunotherapy technique allows in vitro detection of monoclonal anti-
tumor antibodies directed against a variety of human cancers (Goncalves & Donadi, 2004; 
Monie, 2007; Scott, 2001).  
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4.3 Active specific immunotherapy 
Active specific immunotherapy has been used to induce therapeutic cellular immunity by 
using intact tumor cells, defined tumor antigens, and immunostimulants. Moreover, 
autochtonous tumor cells genetically modified to produce immunostimulatory molecules 
are being evaluated in clinical trials (Monie, 2007; Norris, 1990; Scott, 2001).  
Granulocyte-macrophage colony stimulating factor (GM-CSF) or interleukin-2 co-
stimulatory molecules such as B7-1 and allogeneic class I MHC molecules are commonly 
used (Monie, 2007; Scott, 2001).  
4.4 Allogeneic tumor cells 
This procedure may be performed in patients with acute lymohoblastic and acute 
myeloblastic leukemia. Irradiated allogeneic tumor cells and bacille Calmette-Guerin 
vaccine (BCG) are used (Monie, 2007; Scott, 2001). 
4.5 Defined tumor antigen based vaccines 
More recently, approaches using defined tumor antigen based vaccines are among the most 
promising techniques. Prolonged remissions have been observed because a defined end-
point is available. There is enough evidence that antigens derived from genes that have 
mutated during tumor development and antigens that have a normal sequence but are not 
expressed in the tumor have been demonstrated as a target of specific T-cells grown from 
cervical cancer patients (Monie, 2007; Norris, 1990; Scott, 2001).  
5. Immunological aspects in cervical cancer 
Immunological aspects of cervical cancer are still of interest, tumor specific immune 
response being one of the most promising fields in cervical cancer research. As HPV is the 
etiological agent of a family of diseases that cause more cancer death in women worldwide 
than any other form of cancer, the goal of the newer trials is to identify novel strategies for 
cervical cancer immunotherapy (Monie, 2007; Scott, 2001).  
HPV types 16 and 18 represent probably the most prevalent oncogenic types found in 
cancerous cervical tissues, accounting for up to 80% of the cervical cancer cases. Moreover, 
the risk of progression to cervical carcinoma is higher for HPV types 16 and 18 than for 
other known types of HPV (Ancuta, 2009; Goncalves & Donadi, 2004; Scott, 2001).  
However, most adult women will completely recover from their HPV infection, with a 
reported clearance rate of 30% at 6 months and 50% at 12 months. Therefore, a persistent 
infection with HPV may be defined as the continued detection of viral DNA of the same 
HPV type for at least 12 months.  
After transmission by sexual contact, it has been demonstrated that the virus does not cause 
viraemia or systemic infection and remains located in the epithelial cells of cervical mucosa.  
It is well known that the virus adaptation to the differentiation of the superficial cells is an 
essential process to evade the host’s immunity. Besides, HPV by itself is not cytolytic for the 
keratinocytes. The squamous epithelium undergoes a programmed cell death and 
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descuamation. HPV infects basal layer of the epithelium that mature vertically to the 
superficial surface of it; therefore, the viruses are released only in the most superficial layers 
of the squamous epithelium into the cervical lumen (Goncalves & Donadi, 2004; Scott, 2001).  
Usually, the entire process from infection to viral release is less than three weeks. The 
natural keratinocytes death is not accompanied by inflammation and, therefore, viral 
proteins are not visible to the host immune system.  
Most of women with early invasive cervical cancer are asymptomatic. In such cases, cervical 
smears may be effective in detecting early stage disease. On the other hand, advanced 
cervical cancer displays two primary pathways of extension: (i) local expansion and (ii) 
lymphatic or hematogenous dissemination. 
It is actually known that mononuclear cells commonly infiltrate cervical tissue in different 
types of carcinoma, particularly in intra-tumoral sites, supporting the immune response 
against tumor. Previous studies have already shown the importance of local immune cell 
response in patient stratification according to the risk of disease recurrence after treatment. 
Moreover, three different cell subsets including TCD3+, BCD20+ and CD45+ leucocytes 
have been extensively studied among women with or without recurrence of their cancer 
after the surgery (Ancuta, 2009). Higher densities infiltrates are thought to be associated 
with a better clinical outcome. In addition, it seems that there is a relationship between 
different types of immune cells and survival: high density of cells is frequently observed in 
connection with free survival (Ancuta, 2009). The strongest discriminatory potential was 
attributed to densities of CD3+ in both intra- and peritumoral tissue; besides, according to a 
multiple regression model, CD3+ seems to be considered a potent prognostic factor for 
relapse (Ancuta, 2009). Nevertheless, no predictive biomarker is still validated for the use in 
clinical practice (Ancuta, 2009). 
5.1 The innate immune system  
The innate immune system generates non-specific protection against non-self antigens and 
does not intensify following repetitive infection events, while the aim of adaptive immunity 
is to induce cell mediated immune response by providing pathogen specific immunological 
memory.  
Inflammation is a complex process that involves the recruitment of macrophages, 
neutrophils, dendritic cells and the release of cytokines and complement components. 
Dendritic cells activated by local cell injuries take up and process microbial agents while 
migrating to the draining lymph nodes, where they become antigen presenting cells and 
interact with T helper lymphocytes. Moreover, they are able to activated differentiation of T 
cytotoxic lymphocytes that allows rapid and strong response directed against the pathogen 
infected cells able to kill the pathogen (effector T-cells) and a fraction of the T cytotoxic and 
T helper cells becomes T memory cells (Arany, 1995; Arany & Tyring, 1996; de Gruijl, 1998; 
Goncalves & Donadi, 2004; Scott, 2001; Moscicki, 2000).  
On the other hand, T helper lymphocytes activate the humoral immune response, which 
results in the production of specific antibodies against viral infection. In addition, these cells 
activate the differentiation of B lymphocytes into plasma cells that will neutralize the virus 
by binding to the viral capside proteins and other plasma cells that are able to synthetize 
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and to secrete antibodies which maintain a protective level of antibodies long time after the 
first contact with the virus (al-Saleh, 1998; Bell, 1995; de Gruijl, 1998; Goncalves & Donadi, 
2004; Scott, 2001).  
B memory cells will provide rapid and amplified antibody response after re-infection with 
the same pathogen. 
HPV is a double stranded DNA virus that contains 8000 base pairs. There is strong evidence 
that two key regions have been described in HPV:  
 the early region which contains eight genes (E1 to E8), involved in the viral DNA 
replication function (E1 and E8), transcription control (E2 and E8) and cellular 
transformation (E5, E6 and E7); 
 the late region, with two genes (L1-L2), which code for the capsid proteins. 
Viral DNA replication remains located mainly in the basal cells of the epithelium’s 
proliferative cells, whereby most individuals eliminate the HPV 12 to 24 months after the 
diagnosis.  
On the other hand, the oncogenic viral types are associated with high grade squamous 
intraepithelial lesions and it is known that the host’s humoral and cellular immune system 
can explain the latency of HPV infection. Also, the responses to cytokine action during 
carcinogenic and non-carcinogenic processes are evidence of the role of immunological 
control in tumoral progression or progress of lesions associated with HPV infection (Ancuta, 
2009; Bethwaite, 1996; Crowley-Nowick , 2000; Scott, 2001). 
The interaction between these mechanisms is responsible for malignant transformation in 
women with HPV infection: 
 one of these involves a modification of the AP1 transcription factor, endogenous 
synthesis of anti-viral interferon beta; 
 the other involves the interaction between INK4A and transforming activity of E6. 
Modern data support the fact that epithelial cells appear to play much more complex roles 
in cell mediated immune response than a mechanical barrier. 
Cervical keratinocytes constitutively secrete pro-inflammatory cytokines, growth factors 
and chemokines. Main cytokines which promote anti-viral effects are represented by 
transforming growth factor beta (TGF-┚), tumor necrosis factor alpha (TNF-┙) and beta 
(TNF-┚) and interferon (IFN), respectively. Several cytokines such as IFN-┙, IFN-┚, TNF-┙ 
and TGF-┚ which are essentially produced by epithelial cells, display significant anti-viral 
and anti-proliferative effects.  
Additionally, a promising mechanism by which TGF-┚, TNF-┙ and the IFNs are able to 
inhibit the in vitro proliferation of both HPV-transformed keratinocytes and expression of 
HPV genes including the early genes E6 and E7 has been advanced (Crowley-Nowick, 2000; 
Scott, 2001).  
It has been demonstrated that E7 interacts with the tumor suppressing retinoblastoma gene 
protein, while E6 has been shown to be critical in cancer development by enhancing protein 
p53 degradation through ubiquitin-mediated proteolysis via a mechanism requiring E6-
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associated protein. Thus, all these data highlighted once more the notion that E6 and E7 
proteins appear to have essential role in malignancy (Youde, 2000; Scott, 2001).  
Varied results of the potential for HPV-infected cells to escape immune response, 
accompanied by the growth inhibitory effects of cytokines, are highly depending on 
experimental findings. 
TGF-┚1 provides a good example of growth inhibitory effect in either HPV type 16 or HPV 
18 transformed cells. Studies investigating the role of exogenous effects of TGF-┚1 showed 
that the TGF-┚1 induce growth inhibition in HPV 16 immortalized human keratinocyte cell 
line may be accompanied by suppression of steady-state levels of RNA down-regulation of 
the genes c-myc, suggesting a mechanistic association between TGF-┚ up-regulation and 
HPV-infected cells. The same researches also reported that over-expression of TGF-┚1 
treatment of HPV 16 immortalized cells results in proliferation enhancing bcl-2 and NFkB 
genes (Goncalves & Donadi, 2004; Scott, 2001).  
HPV infected cells are grown in a medium that stimulates early stages of tumor progression; 
therefore, TGF-┚ appears to stimulate cells growth. The effect is seen only in HPV infected 
cells, but not in HPV negative ones, favoring increased expression of epidermal growth 
factor receptor and its ligand. These examples suggest that HPV infected cells may escape 
early, even before malignant transformations occurs.  
The evaluation of the growth inhibitory effects of TNF-┙ in HPV infected cells has revealed 
that TNF-┙ appears to have an anti-proliferative effect on HPV 16 infected cells. The 
characterization of this growth inhibitory effect has lead to the suggestion that it involves 
growth arrest in G0-G1 phase.  
As recently reviewed by certain authors, a growth-stimulatory effect involving an 
amphiregulin-mediated autocrine loop has been demonstrated for both IL-10 and TNF-┙ in 
some HPV 16 or 18 infected epithelial cells. They finally concluded that it could provide an 
early escape from growth inhibition in HPV-immortalized cells. In addition to the anti-
proliferative effect, IFNs have also been investigated.  
It seems that IFN-┙ inhibits the proliferation of HPV 16 infected cells at lower dose as 
compared to those needed to inhibit the growth of normal keratinocytes. It has also been 
shown that IFN-┙ inhibits E7 protein expression without interfering with transcription, 
suggesting that the inhibition of proliferation is mediated through E7 protein but not E6 
protein expression. Moreover, the authors have concluded that IFNs may be virus-type 
specific or cell-line specific. A direct potential anti-viral role for IFNs in HPV-infected cells 
was therefore identified (Hatch & Fu, 1999; Nakagawa, 2000; Scott, 2001; Wang, 1999).  
Interestingly, neither IFN-┙ and IFN-┛ have been shown to reduce the transcription of E6 
and E7 genes in a HPV 16 transformed keratinocyte line (HPK-1A) (Kleine, 1995; Lee, 1999; 
Scott, 2001). More recent work indicates that IFN-┚ reduces the transcription of both E6 and 
E7 genes in HPV 16 transfected keratinocyte-line (HPK-1A). Besides, there is actually strong 
evidence that malignant transformation is accompanied by the loss of responsiveness to the 
inhibitory properties of cytokines. TGF-┚, for example, may play roles in checking the HPV 
gene transcription in non-tumorigenic HPV 16 immortalized cell type lines and malignant 
transformation could involve partial resistance to it (Nakagawa, 2000; Scott, M, 2001; Stoler, 
2010).  
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The hypothesis that the resistance to the growth-inhibitory effects of several cytokines may 
occur in HPV-immortalized cells even prior to malignancy is actually proposed. The authors 
suggested that chronic inflammation has led to a selective advantage for abnormal cells in 
vivo by synthesis of pro-inflammatory cytokines. They concluded that a possible escape of 
cytokine mediated growth inhibition in HPV infected cells was identified. 
The studies described above suggest the possibility that HPV infected cells may evade the 
growth inhibitory effects of cytokines by modulating the production of cytokines and other 
mechanisms. For example, they have more recently demonstrated that a correlation between 
increased tumorigenicity, significantly decreased expression of TNF┙ receptors and 
resistance to TNF-mediated inhibition of proliferation was observed. The studies concluded 
that type I and type II receptors levels in serum of patients with HPV 16 or 18 cervical 
carcinoma were significantly increased (Bontkes, 1999; Scott, 2001). 
The characterization of this effect has led to the suggestion that soluble type I and type II 
TNF-┙ receptors may facilitate the growth of lesions in the HPV infected epithelium. As a 
further example, a possible mechanism by which HPV infected cells may escape the anti-
proliferative cytokines effect, that conversion of non-tumorigenic He La fibroblast hybrids to 
malignant cells is accompanied by the ability of TNF-┙ to suppress HPV 18 gene 
transcription, suggesting a mechanistic association between loss of TNF-┙ sensitivity and 
alterations in the composition of the activator protein 1 complex.  
HPV 16 E7 inactivates the induction of the IFN-┙ inductible genes by blocking the 
translocation of p48, the DNA binding part of the IFN stimulated gene factor 3 transcription 
complex, to the molecules upon IFN-┙ stimulation. The characterization of this cytokines 
role, except IFN-┛, in keratinocyte growth regulation in HPV infected cells has led to the 
observation that these may play autocrine roles in HPV infection (Goncalves & Donadi, 
2004; Kleine, 1995; Lee, 1999; Norris, 1990; Scott, 2001; Symington & Santos, 1990).   
5.2 Adaptive cell mediated immunity 
The findings provide preliminary evidence for an association between two phases 
(recognition and effector), focusing on the cells involved and membrane bound molecules 
that mediate the immune response.  
5.2.1 Recognition phase 
Several studies have addressed the potential role of Langerhans cells in HPV lesions which 
may contribute to persistence of the infection. For example, S100+cells (antibodies) are 
significantly reduced in SIL compared to normal cervical epithelium, whereas CD1+ 
(antibodies) cells are not. As recently reviewed, cytokines with some contribution from 
Langerhans cells appear to be crucial mediators of the recognition phase. It seems that IL-1┚, 
IL-1┙, TNF-┙ and IL-10 are involved in Langerhans cells migration, acting as promoters or 
inhibitors of these cells.  
Several investigators have described a possible association between HPV infection and 
deficits in production of these cytokines, based on findings of reduced IL-1┙, IL-1┚, TNF-┙ 
and GM-CSF and cervical carcinoma lines.  
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Besides, there is a relationship between diminished production of certain cytokines and 
persistent HPV infection. For example, TNF-┙ expression was highly expressed in low-
grade squamous intraepithelial lesions (LSIL) biopsy specimens as compared to HSIL 
specimens. These abnormalities may contribute, along with local other immune processes, to 
an altered antigen-presentation to T cells in pre-invasive cervical lesions. Thus, abnormal 
immune responses suggest the possibility that HPV may evade immune-surveillance 
(Bethwaite, 1996; Goncalves & Donadi, 2004; Scott, 2001).  
5.2.2 Effector phase 
5.2.2.1 T-cell responses to HPV infection 
Different analyses have suggested the potential role of T helper lymphocytes in providing 
protection against the persistence of HPV infection by measuring T-cell proliferative 
responses (Ancuta, 2009). It seems that more frequent responses to HPV 16 antigens E6 and 
E7 gene products were observed in subjects who had developed SIL compared to those who 
were cytologically normal, indicating that these antigens are important in SIL prevention.  
In a similar study focused on HPV 16 proteins other than E6 and E7 (HPV 16 E2, HPV 16 E5, 
HPV 16 L1), T-cell proliferative responses to HPV 16 showed no association with disease 
outcome.  
Moreover, results from certain trials have been equally confused by several factors including 
differences in subject populations, antigens (making the interpretation of T-cell helper 
response to HPV infection difficult) and the activities of T helper cells themselves (these are 
involved in production of auto-antibodies by B lymphocytes). 
Other researchers have shown that responses to HPV 16 E5 proteins are more frequently 
observed in subjects with progressing LSIL than subjects without LSIL and those with HSIL. 
The results revealed that these responses may be correlated with clearance of HPV infection 
than with resolution of SIL.  
Since T helper lymphocytes have important roles in aiding the development of cytotoxic 
lymphocytes, a possible association between these cells and clearance of virus may not be 
accurate reflections of a correlation between T helper cells responses and the HPV infection 
(Arany, 1995; Bethwaite, 1996; Dolei, 1999; Goncalves & Donadi, 2004; Nakagawa, 2000; 
Scott, 2001).  
5.2.2.2 Research on CTL-mediated killing 
Few studies have demonstrated the presence of activated CTL in SIL. CD8+CTL are known 
to be responsible for recognizing and killing HPV infection and SIL. One such study has 
reported that subjects with positive responses to E6 or E7 peptide can lead to the regression 
of tumors expressing E6 or E7; additionally, this regression is mediated by TCD8+, MHC 
class-I-CTL. Also, HPV E6 and/or E7 specific CTL were observed in patients with cervical 
carcinoma. Moreover, it has been demonstrated that CTLs were not only be capable of 
leasing HLA-matched, but also identified HPV specific CTL in lymph nodes and cervical 
cancer. Across sectional analysis of HPV16 E6 and/or E7-specific CTL showed that these 
were lower in women with HPV 16 infection who have developed SIL than in women with 
HPV 16 infection who had not developed SIL.  
www.intechopen.com
Predictive Value of Cellular Immune Response and Tumor Biomarkers in  
Patients Surgically Treated for Cervical Cancer in Relation to Clinical Outcomes 
 
419 
Lack of CTL response to the HPV 16 E6 protein is more frequently observed in subjects with 
persistent HPV infection, suggesting that CTL response to E6 was correlated with viral 
clearance. However, additional studies are necessary for defining the role of CTL in the 
regression of SIL. 
Some researchers reported positive tetramer responses to HPV 16 E7 by isolating T 
lymphocytes specific for HPV, but the interpretation is difficult since the development of 
cervical cancer was not prevented (Bethwaite, 1996; Nakagawa, 2000; Scott, 2001; Sheu, 
1999).  
5.2.2.3 Studies of antigenic epitopes in HPV infection  
There is little information about antigenic epitopes of HPV using mouse model systems and 
human systems, respectively. Nevertheless, certain research papers focusing on CTL 
epitopes of HPV 16 E6 and E7 proteins have identified five common HLA types; also, the 
immunological response of nine of these potential epitopes for HLA-2.1 was demonstrated. 
For example, E6 (29-38), E7 (11-20), E7 (82-90) and E7 (86-93) were identified using HLA-2.1. 
Immunogenicity of three of the four peptides [E7 (11-20), E7 (82-90) and E7 (86-93)] was 
confirmed by using CTL induction of peripheral blood mononuclear cells (PBMCs) from 
humans in vitro. The fourth of these peptides (CTL4) has been observed in SIL and cervical 
cancer (de Gruijl , 1998; Youde, 2000; Scott, 1999; Scott, 2001; Wang, 1999).  
5.2.2.4 MHC class II restricted antigen presentation in the effector phase  
A couple of recent studies have concluded that transcription of class II MHC molecules may 
be due to interferon gamma treatment of HPV 16 or 18 immortalized keratinocytes. They 
have demonstrated that HLA-DR epithelial cells, T-cells and Langerhans cells may 
participate in immune reactions by down-regulating HLA-DR due to interferon gamma 
secretion by activated T cells.  
The hypothesis that up-regulation of HLA-DR expression was absent in cutaneous warts 
was suggested based on differences between cutaneous and mucosal anti-HPV immune 
responses. Also, other authors have reported that expression of HLA-DR is associated with 
HSIL and HPV may evade immune responses by blocking up-regulation of MHC class II 
expression. In addition, impaired up-regulation of this antigen in patients with genital 
condylomas responded to interferon treatment compared to those who did not; a possible 
causal link between high E7 expression in the non-responders and the lower inducibility of 
HLA-DR expression was identified (Crowley-Nowick, 2000; de Gruijl, 1998; Goncalves & 
Donadi, 2004; Youde, 2000; Scott, 2001; Wang, 1999).  
5.2.2.5 MHC class I restricted antigen presentation in the effector phase  
While normal keratinocytes constitutively express MHC class I molecules, HPV-infected 
tissues also commonly express high MHC class I levels as suggested by one report. Besides, 
these keratinocytes are susceptible to class I mediated lysis by alloantigen-primed CTL.  
In a recent analysis, loss of MHC class I expression have been reported in cutaneous warts, 
although only partial loss of expression was seen in condylomas. In addition, studies using 
specimens from cervical cancers biopsies have reported a drastic reduction in MHC class I 
expression.  
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Finally, many investigators have described a possible correlation between loss of MHC class 
I in cervical cancer biopsy specimens and tumor type, disease stage and HPV 16 or 18 types. 
They concluded that loss or down-regulation if MHC class I expression is associated with 
more frequent disease recurrences.  
Another research group has demonstrated that expression of the transporter associated with 
antigen presentation (TAP-1) is also associated with recurrence of the disease, suggesting 
that HPV may evade immune-surveillance by down-regulating TAP-1. As well, loss or 
down–regulation of MHC class I expression is critical for CTL-mediated killing (Bethwaite, 
1996; Crowley-Nowick, 2000; de Gruijl, 1998; Youde, 2000; Scott, 2001; Wang, 1999).  
5.3 Regulation of T cell immune responses 
5.3.1 Chemokines and adhesion molecules 
Another area of interest is the recruitment of activated lymphocytes at the sites of 
inflammation, defining immune processes that involve both chemokines and membrane 
bound adhesion molecules.  
Several studies have described a close association between IL-8 production and the 
recruitment of neutrophils and T cells, while other have reported that malignant 
transformation of cervical keratinocytes is associated with higher IL-8 levels, especially 
when stimulated by IL-1 or TNF-┙. In addition, T cells synthesis and secretion of IFN-┛ may 
be accompanied by high IL-8 levels, stimulating, in turn, cellular immune responses.  
Certain novel papers on malignant transformation have also mentioned higher IL-8 levels in 
women with histologic evidence of HPV infection, whereas the levels of RANTES 
(Regulated on Activation Normal T Expressed Secreted Factor) and MIP-1┙ (Macrophage 
Inflammatory Protein-1 alpha) are confounded. On the other hand, some approaches 
suggest that IL-8 synthesis in HPV 16 or 18 immortalized cell lines was significantly 
diminished.  
Cervical keratinocytes are capable of producing MCP-1 (Macrophage Chemo-attractant 
Protein 1) and HPV 18+ HeLa cells transfected without the vector containing cDNA for 
MCP-1 lead to rapidly growing tumors. Some recent data suggest that ICAM-1 (Intercellular 
Adhesion Molecule-1) and its ligand, LFA-1 (Leukocyte Function Associated Antigen 1), 
seems to be important in adhesion processes by involving specific antigen recognition and 
CTL mediated killing.  
Advanced researches have proposed the hypothesis that the adhesion process is 
accompanied by increased expression of ICAM-1 as a result of TNF-┙ and IFN-┛ 
contribution. In addition, small clusters of LFA-1 positive T cells were found in the lower 
half of the epithelium surrounding ICAM-1 positive keratinocytes. Furthermore, the 
communication between T cells and keratinocytes is believed to be supported by the ICAM-
1 overlapped with HLA-DR expression as bystanders of the adhesion process.  
Whereas old data support the observation that impaired expression may play a role in the 
progression of the malignant process, the role of adhesion molecules in cervical cancer was 
recently up-dated (Bethwaite, 1996; Bell, 1995; Dolei, 1999; Monnier-Benoit, 2006; Scott, 2001; 
Wang, 1999).   
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5.3.2 Cytokines regulating T-cell responses  
In the last years, many articles have reviewed the classification of activated T-helper cells 
aiming to understand humoral and cellular immune responses in cervical cancer (Ancuta, 
2009).  
A larger number of cells with particular focus on Th1 and Th2 cytokines production may play 
a role in local immune response. The classification include IFN-┛, TNF-┙ and IL-2 producing T 
helper type 1 cells which stimulate cellular immune response and IL-4, IL-5, IL-10 and IL-13 
producing T helper type 2 cells, which in turn stimulate humoral immune response.  
The observation that Th1-Th2 paradigm may play a role in HPV infection has support from 
several studies. Th1 cytokines such as IFN-┛ and IL-2 may also be important in the natural 
history of HPV infection (Mosmann & Sad; 1996; Scott, 1999; Scott, 2001). 
Moreover, immunohistochemmical analysis has been proposed by many researchers to 
study cervical cancer biopsy specimens; they compared immunohistological studies of 
cervical carcinoma with results from normal cervical epithelium demonstrating fewer Th1 
cells (IL-2+) and higher density of Th2 cells (IL-4+).  
The authors have suggested that the IL-2 synthesis may be related to HPV type 16 in vitro 
stimulation. For example, the lowest IL-2 levels were demonstrated in women with cervical 
cancer, while the highest levels of IL-2 were reported in cytologically normal HPV women. 
Besides, there is strong evidence that MHC class I and/or MHC class II molecules down-
regulation may decrease immune recognition of HPV-associated tumors through 
modulating IL-10 production (Bethwaite, 1996; Dolei, 1999; Goncalves & Donadi, 2004; 
Monnier-Benoit, 2006; Wang, 1999). 
5.4 Clearance of HPV infection and clinical implications 
As emphasize by some authors, HPV may evade local immune response by limiting the 
extent of viral antigens to immunologic recognition.  
Three potential mechanisms for HPV immune-surveillance were actually proposed, 
including: 
 E7 protein may inhibit local immune response by blocking the antigen presenting 
function of dendritic cells from the epithelium in cervical tissue; 
 an effective immune response against the HPV infected cells in the basal epithelium, 
where the E6 and E7 early genes are expressed; capsid encoding genes delayed 
expression may be the consequence of the inhibition promoted by a codon usage still 
remain exploratory, but this scenario is still exploratory; 
 lack of CTL response to the HPV infected cells: keratinocytes may be less susceptible to 
class I mediated lysis by alloantigen-primed CTL (Bethwaite, 1996; Dolei, 1999; 
Goncalves & Donadi, 2004; Palefsky, 1999; Scott, 2001; Wang, 1999) 
6. Prophylactic HPV vaccines  
Multiple studies indicate there are several challenges and uncertainties that need to be 
resolved before HPV vaccination. In addition, socio-cultural factors will affect the 
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acceptability of the HPV vaccine in high risk developing countries. Patients must acquire 
more information for accepting HPV vaccination. After considering the evidence, the 
clinicians come to a unanimous decision that such information might include the need for 
prevention and applicable information concerning where to acquire and how to fund HPV 
vaccination.  
Two prophylactic HPV vaccines, namely CervarixR and GardasilR (Silgard), have been 
already approved; they are directed against and contain virus-like particles (VLPs) specific 
for two of the most important oncogenic HPV types 16 and 18. In addition, GardasilR is a 
quadrivalent vaccine that also includes VLPs for HPV 6 and 11, the most common HPV 
types found in up to 90% of genital warts (Harper, 2009; Kitcher, 2008). These vaccines offer 
protection for 70% of cancers, but also for about 90% of HPV type 16/18 associated CIN 
(Kitcher, 2008).  
Although the immunogenic properties of the prophylactic HPV vaccines give the possibility 
of long term protection for women in a wide range of years, the vaccination seems to be 
most advantageous in preadolescent girl (Kitcher, 2008). It is widely recognized that the 
above mentioned prophylactic vaccines are able to induce high titers of neutralizing 
antibodies; however, CervarixR is responsible for significantly higher titers of antibodies 
than GardasilR (Harper, 2009).  
With regard to baseline seropositivity, increased memory B cell response is commonly 
reported in women who were both seronegative and PCR negative for oncogenic HPV types 
16 and 18 at the time of vaccination (Harper, 2009). Also, several studies showed that 
adolescents mounted an antibody response that was significantly higher compared to the 
seronegative old women (Harper, 2009). Because the meaning of loss of antibody titers is 
unclear, long term studies are necessary to prove the efficacy for the HPV vaccines. 
In general, both GardasilR and CervarixR are safe for the majority subjects who received 
vaccines. The most commonly reported adverse events were pain, erythema, swelling, 
myalgias, arthralgias, headaches and gastrointestinal symptoms. In the mean time, no 
serious adverse events (hospitalization, disability, death) have been reported (Harper, 2009).  
Special consideration should be made about vaccine administration in pregnancy; three 
therapeutic scenarios are defined, as follows: 
- the vaccination during pregnancy is not allowed; 
- if one dose of vaccine has been received before pregnancy, all three administration 
should be taken after delivery; 
- if two doses have been received before pregnancy, the last dose could be administrated 
in postpartum period (Harper, 2009). 
No scientific evidence supports the interruption of a pregnancy because of the partial 
vaccine administration; additionally, there is no formal contraindication to vaccination 
during lactation (Harper, 2009).  
7. Conclusions 
Developments in the technology of measuring HPV antibody response in serum specimens 
would facilitate directions for further research in the prevention, control and management 
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in cervical cancer and might encourage additional clinical trials research on HPV infection 
and cervical carcinoma that need to be widely disseminated to the clinicians and women by 
updating screening and management protocol. 
The current perception of HPV persistency is not fully understand by many physicians and 
researchers. Therefore, viral persistency will be taken into account in an organized context 
in screening programs.  
Because of the very high efficacy shown by HPV vaccines, the cytology-based screening 
programs will be less efficient and potentially rates of over-diagnosis and over-treatment of 
indefinite lesions will multiply.  
Transition time to redefine screening protocols including a later age at the beginning and 
less frequent screening visits is thus essential.  
In addition to HPV-based screening programs, many issues are not fully comprehend, 
requiring a lot of educations: triage of cytological pre-invasive lesions, follow-up after 
treatment of SIL, detection of p16, detection of HPV mRNA, prophylactic vaccination 
against HPV infection.  
Baseline assessment of women with cervical carcinoma with and without relapse is critical 
in order to identify association with classical negative prognostic factors including tumor 
size and grading, histological type, clinical stage FIGO and lymph node invasion. 
The assessment of local cellular immune response seem to be critical for stratifying patients 
according to their risk, for the therapeutic option; moreover, understanding of local immune 
response in cervical carcinoma may potentially guide new adjuvant treatment strategies 
including immunotherapy.  
Several studies have already demonstrated that tumor-infiltrating lymphocytes 
(composition, distribution, cell count) reflect the status of the cellular immune system in 
patients with cervical cancer. Different immune cell subsets, especially T-cells 
subpopulation, were assessed in tissue specimens from different types of cervical carcinoma; 
despite some controversial data, the majority of researchers have indicated that tumor 
infiltration by immune cells are associated with improved clinical outcome in cancer 
patients, especially in cervical cancer. 
To identify the immune cells of interest, the specific antigens expressed on cell surface could 
be detected by immunohistochemistry, using corresponding antibodies. There is some 
evidence that immunohistochemistry assessment in women experiencing recurrence of their 
cervical cancers has revealed low densities of immune cells infiltrating the tumor.  
There is actually enough evidence to promote the hypothesis that local cellular immune 
response is essential for guiding further cancer evolution and prognosis. However, larger 
cohort studies based on extended analysis of several immune cells are critical for the 
validation of prognostic biomarkers in cervical cancer. 
8. References  
al-Saleh, W.; Giannini, L.M, Jacobs, N., Moutschen, M., Doyen, J., Boniver, J., Delvenne, P. 
(1998). Correlation of T-helper secretory differentiation and types of antigen-
www.intechopen.com
 Hysterectomy 
 
424 
presenting cells in squamous intraepithelial lesions of the uterine cervix. J. Pathol., 
Vol. 184, pp.283–290, ISSN: 1096-9896 
Arany, I.; Goel, A., Tyring, S.K. (1995). Interferon response depends on viral transcription in 
human papillomavirus-containing lesions. Anticancer Res, Vol. 15, pp.2865–2869, 
ISSN: 0250-7005 
Arany, I. & Tyring, S.K. (1996). Activation of local cell-mediated immunity in interferon-
responsive patients with human papillomavirus-associated lesions. J. Interferon 
Cytokine Res. Vol. 16, pp. 453–460, ISSN: 1079-9907 
Ancuta, E.; Ancuta, C., Zugun-Eloae, F., Iordache, C., Chirieac, R., Carasevici, E. (2009). 
Predictive value of cellular immune response in cervical cancer, RJME, Vol. 50, No. 
4, pp.651–655, ISSN, 1220-0522 
Bethwaite, P.B.; Holloway, L.J.; Thornton, A.; Delahunt, B. (1996). Infiltration by 
immunocompetent cells in early stage invasive carcinoma of the uterine cervix: a 
prognostic study, Pathology, Vol. 28, No. 4, pp. 321–327, ISSN: 09728074 
Bell, M.C.; Edwards, R.P.; Partrige, E.E., Kuykendall, K.; Conner, W.; Gore, H.; Turbat-
Herrara, E.; Crowleynowick, P.A. (1995). CD8+ T lymphocytes are recruited to 
neoplastic cervix, J Clin Immunol, Vol. 15, No. 3, pp. 130–136., ISSN: 1573-2592 
Bontkes, H. J.; de Gruijl, T.D., Bijl, A., Verheijen, R.H., Meijer, C.J., Scheper, R.J., Stern, P.L., 
Burns, J.E., Maitland, N.J., Walboomers, J.M. (1999). Human papillomavirus type 16 
E2-specific T-helper lymphocyte responses in patients with cervical intraepithelial 
neoplasia. J. Gen. Virol. Vol. 80, pp.2453–2459, ISSN: 0022-1317 
Chao, H.T.; Wang, P.H., Tseng, L.Y., Lai, C.R., Chiang, S.C., Yuan, C.C. (1999). Lymphocyte-
infiltrated FIGO Stage IIB squamous cell carcinoma of the cervix is a prominent 
factor for disease-free survival, Eur J Gynaecol Oncol, Vol. 20, No. 2, pp.136–40. 
ISSN: 0392-2936. 
Crowley-Nowick, P.A.; Ellenberg, J.H., Vermund, S.H., Douglas, S.D., Holland, C.A., 
Moscicki, A.B. (2000). Cytokine profile in genital tract secretions from female 
adolescents: impact of human immunodeficiency virus, human papillomavirus, 
and other sexually transmitted pathogens. J. Infect. Dis, Vol. 181, pp.939–945, 
ISSN:0022-1899 
de Gruijl, T. D.; Bontkes, H.J., Walboomers, J.M., Stukart, J., Doekhie, F.S., Remmink, A.J., 
Helmerhorst, J., Verheijen, R.H., Duggan-Keen, M.H., Stern, P.L., Meijer, P., 
Scheper, R.J. (1998). Differential T helper cell responses to human papillomavirus 
type 16 E7 related to viral clearance or persistence in patients with cervical 
neoplasia: a longitudinal study. Cancer Res, Vol. 58, pp.1700–1706, ISSN: 0008-5472. 
Dolei, A.; Curreli, S., Marongiu, P., Pierangeli, A., Gomes, E., Bucci, M., Serra, C., Degener, 
A.M. (1999). Human immunodeficiency virus infection in vitro activates naturally 
integrated human papillomavirus type 18 and induces synthesis of the L1 capsid 
protein. J. Gen. Virol, Vol. 80, pp.2937–2944, ISSN: 0022-1317 
Goncalves, M.A.G. & Donadi, E.A. (2004). Immune cellular response to HPV: current 
concepts, Braz Journal Infect Dis, Vol. 8, No. 1, pp.1–9., ISSN 1413-8670 
Hatch, D.K. & Fu, Y.S. (1999). Cervical and vaginal cancer. In: Novak’s Gynecology, Berek, J.S. 
Callisto Medical Press, Turkey, 1111–55. 
Harper,D.M. (2009). HPV vaccines. In: Textbook of Gynaecological Oncology, Ayhan, A.; 
Gultekin, M. & Dursun, P. (Eds), Gunes Publishing. 
www.intechopen.com
Predictive Value of Cellular Immune Response and Tumor Biomarkers in  
Patients Surgically Treated for Cervical Cancer in Relation to Clinical Outcomes 
 
425 
Youde, S. J.; Dunbar, P.R., Evans, E.M., Fiander, A.N., Borysiewicz, L.K., Cerundolo, V., 
Man, S. (2000). Use of fluorogenic histocompatibility leukocyte antigen-
Ap0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-
lymphocyte-recognizing endogenous human papillomavirus antigens. Cancer Res. 
Vol. 60, pp.365–371, ISSN: 0008-5472. 
Kitchener, H.C. (2008). Prophylactic HPV vaccination: current status. In: Vaccines for the 
prevention of cervical cancer, Stern, L.P. & Kitchener, H.C. (Eds), Oxford University 
press; ISBN; 978-0-19-954345.  
Kleine, K.; Konig, G., Kreuzer, J., Komitowski, D., Zur Hausen, H., Rosl, F. (1995). The effect 
of the JE (MCP-1) gene, which encodes monocyte chemoattractant protein-1, on the 
growth of HeLa cells and derived somatic- cell hybrids in nude mice. Mol. Carcinog. 
Vol. 4, pp.179–189, ISSN: 0899-1987. 
Lee, B.N.; Follen, M., Tortolero-Luna, M., Eriksen, N., Helfgott, A., Hammill, A., Shearer, 
W.T., Reuben, J.M. (1999). Synthesis of IFN-gamma by CD8(1) T cells is preserved 
in HIV-infected women with HPV-related cervical squamous intraepithelial 
lesions. Gynecol. Oncol, Vol. 75, pp.379–386, ISSN 0090-8258. 
Monie, A.; Hung, C.F.; Wu, T.C. (2007). Preventive and therapeutic HPV vaccines, Curr Opin 
Invest Drugs, Vol.8, No.12, pp.1038–50, ISSN: 1472-4472 
Monnier-Benoit, S.; Mauny, F., Riethmuller, D., Guerrini, J.S., Capilna, M., Felix, S., Seilles, 
E., Mougin, C., Pretet, J.L. (2006). Immunohistochemical analysis of CD4+ and 
CD8+ T-cells subsets in high risk human papillomavirusassociated pre-malignant 
and malignant lesions of the uterine cervix, Gynecol Oncol, Vol. 102, No. 1, pp.22–31, 
ISSN 0090-8258 
Moscicki, A.B.; Ellenberg, J.H., Vermund, S.H., Holland, C.A., Darragh, T., Crowley-
Nowick, A., Levin, L., Wilson, C.M. (2000). Prevalence of and risks for cervical 
human papillomavirus infection and squamous intraepithelial lesions in adolescent 
girls: impact of infection with human immunodeficiency virus. Arch. Pediatr. 
Adolesc. Med, Vol. 154, pp.127–134, ISSN 1072-4710. 
Mosmann, T.R. & Sad, S. (1996). The expanding universe of T-cell subsets: Th1, Th2 and 
more. Immunol. Today, Vol. 17, pp.138–146, ISSN: 0167-4919 
Nakagawa, M.; Stites, D.P., Patel, S., Farhat, S., Scott, M., Hills, N.K., Palefsky, J.M., 
Moscicki, A.B. (2000). Persistence of human papillomavirus type 16 infection is 
associated with lack of cytotoxic T lymphocyte response to the E6 antigens. J. Infect. 
Dis. Vol. 182, pp.595–598, ISSN:0022-1899 
Nedergaard, B.S.; Ladekarl, M., Thomsen, H.F., Nyegaard, J.R., Nielsen, K. (2007). Low 
density of CD3+, CD4+ and CD8+ cells is associated with increased risk of relapse 
in squamous cell cervical cancer, Br J Cancer, Vol. 97, No. 8, pp. 1135–1138, 
ISSN:0007-0920 
Nedergaard, B.S.; Ladekarl, M., Nyegaard, J.R., Nielsen, K. (2008). A comparative study of 
cellular immune response in patients with stage IB cervical squamous cell 
carcinoma. Low number of several immune cell subtypes are strongly associated 
with relapse of disease within 5 years, Gynecol Oncol, Vol. 108, No. 1, pp.106–111, 
ISSN 0090-8258 
Norris, D.A. (1990). Cytokine modulation of adhesion molecules in the regulation of 
immunologic cytotoxicity of epidermal targets. J. Investig. Dermatol. Vol. 95, 
pp.111S–120S, ISSN: 0022-202X 
www.intechopen.com
 Hysterectomy 
 
426 
Palefsky, J.M.; Minkoff, H., Kalish, L.A., Levine, A.L., Sacks, S., Garcia, P., Young, M., 
Melnick, S., Miotti, P., Burk, R. (1999). Cervicovaginal human papillomavirus 
infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-
negative women. J. Natl. Cancer Inst. Vol. 91, pp.226–236, ISSN 0027-8874 
Piersma, S.J.; Jordanova, E.S., van Poelgeest, M.I.E., Kwappenberg, K.M.C., van der Hulst, 
J.M., Drijfhout, J.W., Melief, C.J.M., Kenter, G.G., Fleuren, G.J., Offriga, R., van der 
Burg, S.H. (2007). High number of intraepithelial CD8+ tumor-infiltrating 
lymphocytes is associated with the absence of lymph node metastases in patients 
with large early-stage cervical cancer, Cancer Res, Vol. 67, No. 1, pp.354–361, ISSN: 
0008-5472 
Scott, M.; Stites, D.P., Moscicki, A.B. (1999). Th1 cytokine patterns in cervical human 
papillomavirus infection. Clin. Diagn. Lab. Immunol. Vol. 6, pp. 751–755. ISSN 
(printed): 1071-412X 
Scott, M.; Nakagawa, M., Moscicki, A.B. (2001). Cell-Mediated Immune Response to Human 
Papillomavirus Infection, Clin Diagn Lab Immunol, pp. 209–220, ISSN (printed): 
1071-412X 
Symington, F.W. & Santos, E.B. (1990). Recognition of keratinocytes by cytotoxic T cells 
specific for conventional HLA class-I alloantigen. J. Investig. Dermatol. Vol. 95, 
pp.224–228, ISSN: 0022-202X 
Sheu, B.C.; Hsu, S.M., Ho, H.N., Lin, R.H., Torng, P.L., Huang, S.C. (1999). Reversed 
CD4/CD8 ration of tumor-infiltrating lymphocytes are correlated with the 
progression of human cervical carcinoma, Cancer, Vol. 86, No.8, pp.1537–1543, 
ISSN: 1097-0142 
Stoler, M.H. (2010). HPV in screening and triage. It is more complicated than you think: 
doctor, which HPV type cause that lesion, Newsletter on HPV, No.20, pp. 4-6  
Wang, B.; Amerio, P., Sauder, D.N. (1999). Role of cytokines in epidermal Langerhans cell 
migration. J. Leukoc. Biol. Vol. 66, pp.33–39, ISSN: 0741-5400 
www.intechopen.com
Hysterectomy
Edited by Dr. Ayman Al-Hendy
ISBN 978-953-51-0434-6
Hard cover, 426 pages
Publisher InTech
Published online 20, April, 2012
Published in print edition April, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This book is intended for the general and family practitioners, as well as for gynecologists, specialists in
gynecological surgery, general surgeons, urologists and all other surgical specialists that perform procedures
in or around the female pelvis, in addition to intensives and all other specialities and health care professionals
who care for women before, during or after hysterectomy. The aim of this book is to review the recent
achievements of the research community regarding the field of gynecologic surgery and hysterectomy as well
as highlight future directions and where this field is heading. While no single volume can adequately cover the
diversity of issues and facets in relation to such a common and important procedure such as hysterectomy,
this book will attempt to address the pivotal topics especially in regards to safety, risk management as well as
pre- and post-operative care.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
E. Ancuta, Codrina Ancuta and D. Sofroni (2012). Predictive Value of Cellular Immune Response and Tumor
Biomarkers in Patients Surgically Treated for Cervical Cancer in Relation to Clinical Outcomes", Hysterectomy,
Dr. Ayman Al-Hendy (Ed.), ISBN: 978-953-51-0434-6, InTech, Available from:
http://www.intechopen.com/books/hysterectomy/predictive-value-of-cellular-immune-response-and-tumor-
biomarkers-in-patients-surgically-treated-for
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
